Abstract
Many plant species and tissues have been investigated as production and delivery vehicles for recombinant pharmaceutical proteins. Examples include cultured cells, whole aquatic plants and transgenic plants expressing recombinant proteins in their leaves, seeds, fruits or tubers/roots. Each platform has unique properties in terms of production time, environmental containment, scalability and overall costs. Plant tissues also differ in their abilities to sort, modify and accumulate proteins. Seeds are naturally adapted for protein accumulation and possess specialized storage organelles that may be exploited to accumulate recombinant proteins, offering stability both in planta and after harvest. Generally, the post-harvest stabilizing effect offered by storage tissues is advantageous for pharmaceuticals, allowing them to be delivered via the mucosal route because they are better able to withstand the harsh microenvironment when protected by the plant matrix. Native storage organelles such as starch granules, protein storage vacuoles and protein bodies thus offer interesting possibilities for the delivery of vaccines and antibodies, as well as novel storage organelles that can be induced ectopically in non-storage tissues. The specialization and distinct intracellular organization of storage tissues also affect the trafficking and modification of recombinant proteins. The N-glycosylation of recombinant glycoproteins often differs subtly depending on the plant species and tissue, reflecting both the availability of different sets of glycan-modifying enzymes and the compartmentalization of the proteins. Where a specific glycan structure is required, it is therefore important to choose the appropriate plant system as a production platform.
Keywords: gamma-zein, Elastin-like polypeptides, hydrophobins, molecular farming, subcellular targeting.
Current Pharmaceutical Design
Title:Subcellular Accumulation and Modification of Pharmaceutical Proteins in Different Plant Tissues
Volume: 19 Issue: 31
Author(s): Anna Hofbauer and Eva Stoger
Affiliation:
Keywords: gamma-zein, Elastin-like polypeptides, hydrophobins, molecular farming, subcellular targeting.
Abstract: Many plant species and tissues have been investigated as production and delivery vehicles for recombinant pharmaceutical proteins. Examples include cultured cells, whole aquatic plants and transgenic plants expressing recombinant proteins in their leaves, seeds, fruits or tubers/roots. Each platform has unique properties in terms of production time, environmental containment, scalability and overall costs. Plant tissues also differ in their abilities to sort, modify and accumulate proteins. Seeds are naturally adapted for protein accumulation and possess specialized storage organelles that may be exploited to accumulate recombinant proteins, offering stability both in planta and after harvest. Generally, the post-harvest stabilizing effect offered by storage tissues is advantageous for pharmaceuticals, allowing them to be delivered via the mucosal route because they are better able to withstand the harsh microenvironment when protected by the plant matrix. Native storage organelles such as starch granules, protein storage vacuoles and protein bodies thus offer interesting possibilities for the delivery of vaccines and antibodies, as well as novel storage organelles that can be induced ectopically in non-storage tissues. The specialization and distinct intracellular organization of storage tissues also affect the trafficking and modification of recombinant proteins. The N-glycosylation of recombinant glycoproteins often differs subtly depending on the plant species and tissue, reflecting both the availability of different sets of glycan-modifying enzymes and the compartmentalization of the proteins. Where a specific glycan structure is required, it is therefore important to choose the appropriate plant system as a production platform.
Export Options
About this article
Cite this article as:
Hofbauer Anna and Stoger Eva, Subcellular Accumulation and Modification of Pharmaceutical Proteins in Different Plant Tissues, Current Pharmaceutical Design 2013; 19 (31) . https://dx.doi.org/10.2174/1381612811319310005
DOI https://dx.doi.org/10.2174/1381612811319310005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Molecular Understanding and Future Treatment Strategies for Pathologic Ocular Neovascularization
Current Molecular Medicine Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?
Current Pharmaceutical Design Programmed Cell Death Mechanisms in Neurological Disease
Current Molecular Medicine Hypolipidemic, Antioxidant and Cardioprotective Effects of the Aqueous Extract from <i>Scorzanera Undulata</i> Tubers in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W. Wiedmann)]
Current Cancer Drug Targets Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Non-Invasive Tests in Animal Models and Humans: A New Paradigm for Assessing Efficacy of Biologics Including Prebiotics and Probiotics
Current Pharmaceutical Design Base-Modified Nucleosides as Chemotherapeutic Agents: Past and Future
Current Topics in Medicinal Chemistry CD44-Targeting for Antitumor Drug Delivery: A New SN-38-Hyaluronan Bioconjugate for Locoregional Treatment of Peritoneal Carcinomatosis
Current Cancer Drug Targets Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas
Current Cancer Drug Targets Role of MicroRNA in the Diagnosis and Therapy of Hepatic Metastases from Colorectal Cancer
MicroRNA The Engaged Role of Tumor Microenvironment in Cancer Metabolism: Focusing on Cancer-Associated Fibroblast and Exosome Mediators
Anti-Cancer Agents in Medicinal Chemistry Fullerenes for Applications in Biology and Medicine
Current Medicinal Chemistry New Approaches to Mechanism Analysis for Drug Discovery Using DNA Microarray Data Combined with KeyMolnet
Current Drug Discovery Technologies Synthesis of 3-methyl-4H-benzo[b][1,4]thiazine-2-carboxylates Using CAN as a Catalyst and Its Conversion Into Guanidines
Current Organocatalysis Curcuminoid Metabolism and its Contribution to the Pharmacological Effects
Current Drug Metabolism Antineoplastic Activities, Apoptotic Mechanism of Action and Structural Properties of a Novel Silver(I) Chelate
Current Medicinal Chemistry Feature Classification and Analysis of Lung Cancer Related Genes through Gene Ontology and KEGG Pathways
Current Bioinformatics Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Can Dietary Antioxidants Reduce the Incidence of Brain Tumors?
Current Drug Metabolism